| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.1 | 0.002 |
| mRNA | bid1870 | gCSI | pan-cancer | AAC | -0.17 | 0.002 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | 0.13 | 0.005 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.092 | 0.006 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.007 |
| mRNA | OSI-906 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.008 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | 0.099 | 0.008 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | 0.097 | 0.009 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.094 | 0.009 |